NCT00531440View on ClinicalTrials.gov

This is a 2-year Follow-up Study to Evaluate the Long-term Effects in Patients Who Completed the Study CRAD001A2307.

PHASE3CompletedINTERVENTIONAL
Enrollment

256

Participants

Timeline

Start Date

November 30, 2001

Primary Completion Date

August 31, 2005

Conditions
Renal Transplantation
Interventions
DRUG

Everolimus (RAD001)

Trial Locations (1)

Unknown

Novartis, Basel

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY